A logo is a big part of any major company's brand identity. It takes a lot of work to create a simple little image that the average consumer can immediately associate with certain features and ...

UBS analyst Matthew Weston maintained a Buy rating on AstraZeneca (AZN – Research Report) today and set a price target of £142.00. The company’s shares opened today at p12,090.00. Easily ...

AstraZeneca to buy EsoBiotec for up to $1 billion Deal aims to enhance cancer cell therapy capabilities AstraZeneca secures global rights to Alteogen's ALT-B4 enzyme AstraZeneca shares up almost ...

British pharmaceutical giant AstraZeneca on Monday announced an agreement to buy Belgian cell therapy firm EsoBiotec for up to $1 billion, expanding its treatments for cancer. EsoBiotec's ...

AstraZeneca PLC (NASDAQ:AZN – Get Free Report) has been given an average recommendation of “Buy” by the ten ratings firms that are currently covering the company, Marketbeat.com reports.

Thought LeaderMina MakarSenior Vice President, Global CVRMAstraZeneca NewsMedical spoke with Mina Makar, Senior Vice President of Global CVRM at AstraZeneca, about groundbreaking research in Heart ...

Here are some before and after pictures of the company's wordmark and logo. Need a break? Play the USA TODAY Daily Crossword Puzzle. Here's a look at how the new wordmark and logo will appear on ...

Walmart is giving its logo the first facelift in nearly two decades, rolling out a new identity that is a subtle nod to its past. The 61-year-old company unveiled Monday a refresh of its brand ...

TD Cowen analyst Steve Scala maintained a Buy rating on AstraZeneca (AZN – Research Report) today. The company’s shares closed yesterday at $66.64. Discover outperforming stocks and invest ...

Take the Coke logo, for example. Now, the Coca-Cola font is iconic in its own right. But if you look a little more closely, it holds something dear to the company’s heart—a nod to happiness.

Bloomberg / Contributor / Getty Images A breast cancer drug being developed by AstraZeneca failed to "achieve statistical significance" in helping patients live longer than with chemotherapy in a ...

AstraZeneca’s booming oncology business has won over cancer patient groups. Having languished down the leaderboard in the past, the drugmaker vaulted (PDF) over many rivals in PatientView’s ...